Guido Pastore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guido Pastore has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Magnani
Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy
2 shared publications - Franco Merletti
University of Turin
2 shared publications - Benedetto Terracini
Ctr per Prevenzione Oncol Piemonte, Trento, Italy
1 shared publication - Dario Gregori
Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35121 Padua, Italy
1 shared publication - Elisa Dama
Molecular Medicine Program, European Institute of Oncology, Milan, Italy
1 shared publication - Luisa Zuccolo
Health Data Science Centre, Human Technopole, Milan, Italy
1 shared publication
Latest Publications
- 10 November 2004
- Vol. 28 (3) , 174-7
[Life expectancy as an indicator of outcome].
Usually survival studies evaluate the percentage of subjects alive or disease-free at a given point in time (cumulative survival percentage). These studies require a lengthy period both for follow up and for the collection of an exhaustive number of cases. In addition, for cancer types with a sharp gradient of cumulative mortality, the estimate may be unstable. On the database of children with Acute Lymphoblastic Leukaemia (ALL) collected by the Childhood Cancer Registry of Piedmont (CCRP) in 1979-1991, we have estimated an alternative time-dimensional index to estimate both patients' life expectancy of patient and number of years gained to death. These estimates have been compared in subsets of the database corresponding to different periods of diagnosis and efficacy of treatment. Life expectancy has been evaluated as the area under the survival curve, on the assumption that after a number of years since diagnosis, survivors have the same mortality rates of the general population. Clinicians are invited to take into consideration the approach described in the present note.
- 10 November 2004
- Vol. 28 (3) , 174-7
[Life expectancy as an indicator of outcome].
Usually survival studies evaluate the percentage of subjects alive or disease-free at a given point in time (cumulative survival percentage). These studies require a lengthy period both for follow up and for the collection of an exhaustive number of cases. In addition, for cancer types with a sharp gradient of cumulative mortality, the estimate may be unstable. On the database of children with Acute Lymphoblastic Leukaemia (ALL) collected by the Childhood Cancer Registry of Piedmont (CCRP) in 1979-1991, we have estimated an alternative time-dimensional index to estimate both patients' life expectancy of patient and number of years gained to death. These estimates have been compared in subsets of the database corresponding to different periods of diagnosis and efficacy of treatment. Life expectancy has been evaluated as the area under the survival curve, on the assumption that after a number of years since diagnosis, survivors have the same mortality rates of the general population. Clinicians are invited to take into consideration the approach described in the present note.
- 17 August 2004
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 43 (7) , 788-791
Time trends of childhood cancer mortality rates: A report from the childhood cancer registry of piedmont, Italy, 1971–1998
Time changes in mortality rates can be used to suggest future trends in the prognosis of childhood cancer. Estimates provided from recent studies led to divergent previsions of future trends. In this study we used data from the population‐based Childhood Cancer Registry of Piedmont (CCRP) in order to measure the decrease in mortality. The study included 1,060 deaths in the period 1971–1998. Analyses were carried out using Poisson regression models and considered separately the total tumours, acute lymphoblastic leukaemia (ALL) and tumours of the central nervous system (CNS). We observed a progressive decline in the mortality rates: for all tumours the estimated annual percentage change was −3.6% (P < 0.05), for ALL it was −5.2%, (P < 0.05) and for CNS tumours it was −3.8% (P < 0.05). The statistical test for effect modification due to age at death was not significant. For all cancer types, the Poisson model fits the data well, corresponding to an exponential decrease of mortality rates and leading to the conclusion that current therapies, despite their proven effectiveness, are not sufficient to cure all cases of childhood cancer. Pediatr Blood Cancer 2004;43:788–791.
- 17 August 2004
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 43 (7) , 788-791
Time trends of childhood cancer mortality rates: A report from the childhood cancer registry of piedmont, Italy, 1971–1998
Time changes in mortality rates can be used to suggest future trends in the prognosis of childhood cancer. Estimates provided from recent studies led to divergent previsions of future trends. In this study we used data from the population‐based Childhood Cancer Registry of Piedmont (CCRP) in order to measure the decrease in mortality. The study included 1,060 deaths in the period 1971–1998. Analyses were carried out using Poisson regression models and considered separately the total tumours, acute lymphoblastic leukaemia (ALL) and tumours of the central nervous system (CNS). We observed a progressive decline in the mortality rates: for all tumours the estimated annual percentage change was −3.6% (P < 0.05), for ALL it was −5.2%, (P < 0.05) and for CNS tumours it was −3.8% (P < 0.05). The statistical test for effect modification due to age at death was not significant. For all cancer types, the Poisson model fits the data well, corresponding to an exponential decrease of mortality rates and leading to the conclusion that current therapies, despite their proven effectiveness, are not sufficient to cure all cases of childhood cancer. Pediatr Blood Cancer 2004;43:788–791.